Conor O’Donovan joined Gossamer Bio Ireland in July 2020 and has served as Senior Vice President, Regulatory Affairs since March 2025. He has led regulatory efforts for seralutinib since January 2021. Mr.O’Donovan brings over 20 years of experience in regulatory affairs, including senior roles at Travere Therapeutics and Orexigen Therapeutics. Earlier in his career, he served as a senior pharmaceutical assessor at the Health Products Regulatory Authority in Ireland. He holds a pharmacy degree from Trinity College Dublin and an M.Sc. in pharmaceutical technology from Atlantic Technological University, Ireland.